The first 3500 years of aspirin history from its roots - A concise summary.

Aspirin is currently the most widely used drug worldwide, and has been clearly one of the most important pharmacological achievements of the twentieth century. Historians of medicine have traced its birth in 1897, but the fascinating history of aspirin actually dates back >3500 years, when willow bark was used as a painkiller and antipyretic by Sumerians and Egyptians, and then by great physicians from ancient Greece and Rome. The modern history of aspirin precursors, salicylates, began in 1763 with Reverend Stone - who first described their antipyretic effects - and continued in the 19th century with many researchers involved in their extraction and chemical synthesis. Bayer chemist Felix Hoffmann synthesized aspirin in 1897, and 70 years later the pharmacologist John Vane elucidated its mechanism of action in inhibiting prostaglandin production. Originally used as an antipyretic and anti-inflammatory drug, aspirin then became, for its antiplatelet properties, a milestone in preventing cardiovascular and cerebrovascular diseases. The aspirin story continues today with the growing evidence of its chemopreventive effect against colorectal and other types of cancer, now awaiting the results of ongoing primary prevention trials in this setting. This concise review revisits the history of aspirin with a focus on its most remote origins.

[1]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[2]  C. Ji,et al.  Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. , 1994, The Journal of biological chemistry.

[3]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. , 2009, Lancet.

[4]  C. Patrono,et al.  Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. , 2017, Journal of the American College of Cardiology.

[5]  Deepak L. Bhatt,et al.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease , 2017, The New England journal of medicine.

[6]  T. Maclagan THE TREATMENT OF ACUTE RHEUMATISM BY SALICIN. , 1876 .

[7]  C. Patrono,et al.  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. , 1982, The Journal of clinical investigation.

[8]  L. Bolognese,et al.  RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.

[9]  R. de Caterina,et al.  Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. , 2014, Journal of the American College of Cardiology.

[10]  S. Rezkalla,et al.  The Role of Aspirin in the Prevention of Cardiovascular Disease , 2014, Clinical Medicine & Research.

[11]  K. Schrör,et al.  Aspirin and lipid mediators in the cardiovascular system. , 2015, Prostaglandins & other lipid mediators.

[12]  L. Craven Experiences with aspirin (Acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. , 1953, Mississippi Valley medical journal.

[13]  R. de Caterina,et al.  Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction. , 1985, The American journal of cardiology.

[14]  K. Nicolaides,et al.  Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis , 2017, American journal of obstetrics and gynecology.

[15]  R. Singer ACETYLSALICYLIC ACID, A PROBABLE CAUSE FOR SECONDARY POST-TONSILLECTOMY HEMORRHAGE: A PRELIMINARY REPORT , 1945 .

[16]  N. Cook,et al.  Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials , 2018, The Lancet.

[17]  J. Curnow THE TREATMENT OF ACUTE RHEUMATISM BY SALICIN. , 1876 .

[18]  P. Glasziou Aspirin after Myocardial Infarction , 1980, The Lancet.

[19]  A. Jaffe,et al.  2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[20]  C. Patrono,et al.  Aspirin and Cancer. , 2016, Journal of the American College of Cardiology.

[21]  W. Sneader,et al.  The discovery of aspirin: a reappraisal , 2000, BMJ : British Medical Journal.

[22]  C. Gerhardt Untersuchungen über die wasserfreien organischen Säuren , 1853 .

[23]  Craven Ll Experiences with aspirin (Acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. , 1953 .

[24]  J. Sundström,et al.  Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study , 2017, Circulation.

[25]  Ralph,et al.  STUDIES ON THE HEMORRHAGIC SWEET CLOVER DISEASE IN THE GROUP* , 2003 .

[26]  A. Korczyn,et al.  Nonsteroidal anti-inflammatory drugs exposure and the central nervous system. , 2014, Handbook of clinical neurology.

[27]  P. Rothwell,et al.  Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. , 2012, The Lancet. Oncology.

[28]  M. LeWinter,et al.  Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. , 1983, The New England journal of medicine.

[29]  The Coronis Collaborative Group Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events , 1991, The Lancet.

[30]  C. Bryan PAPYRUS EBERS. , 1931, Bulletin of the Medical Library Association.

[31]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[32]  D. Jack One hundred years of aspirin , 1997, The Lancet.

[33]  M. Packham,et al.  THE EFFECT OF ACETYLSALICYLIC ACID ON PLATELET FUNCTION , 1968, The Journal of experimental medicine.

[34]  H. Collier,et al.  Analgesic antipyretic drugs as antagonists of bradykinin. , 1960, British journal of pharmacology and chemotherapy.

[35]  P. Glasziou Aspirin after myocardial infarction , 1989, Lancet.

[36]  R. Amann,et al.  Anti-inflammatory effects of aspirin and sodium salicylate. , 2002, European journal of pharmacology.

[37]  Walter Sneader,et al.  Drug Discovery (The History) , 2005 .

[38]  L. Aledort,et al.  The effect of salicylates on the hemostatic properties of platelets in man. , 1968, The Journal of clinical investigation.

[39]  G. Born,et al.  Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal , 1962, Nature.

[40]  V. Tsatsaris,et al.  Aspirin for Prevention of Preeclampsia , 2017, Drugs.

[41]  P C Elwood,et al.  A Randomized Controlled Trial of Acetyl Salicyclic Acid in the Secondary Prevention of Mortality from Myocardial Infarction , 1974, British medical journal.

[42]  Suzanne G. Orchard,et al.  Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly , 2018, The New England journal of medicine.

[43]  W. Lands,et al.  Purification of the cyclooxygenase that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme. , 1976, The Journal of biological chemistry.

[44]  G J Roth,et al.  Acetylation of prostaglandin synthase by aspirin. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Mann Murder, Magic, and Medicine , 1992 .

[46]  H. Dreser Pharmakologisches über Aspirin (Acetylsalicylsäure) , 1899, Archiv für die gesamte Physiologie des Menschen und der Tiere.

[47]  R. Collins,et al.  Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus , 2018, The New England journal of medicine.

[48]  P. Rothwell,et al.  Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial , 2018, The Lancet.

[49]  D. Keeling,et al.  The aspirin story – from willow to wonder drug , 2017, British journal of haematology.

[50]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[51]  Nicola Persico,et al.  Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia , 2017, The New England journal of medicine.

[52]  R. de Caterina,et al.  Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function. , 1985, European heart journal.

[53]  P. Gibson Aspirin in the treatment of vascular diseases. , 1949, Lancet.

[54]  K. P. Link,et al.  STUDIES ON THE HEMORRHAGIC SWEET CLOVER DISEASE XI. HYPOPROTHROMBINEMIA IN THE RAT INDUCED BY SALICYLIC ACID , 1943 .

[55]  J. Vane,et al.  Release of Additional Factors in Anaphylaxis and its Antagonism by Anti-inflammatory Drugs , 1969, Nature.

[56]  J. Wood From plant extract to molecular panacea: a commentary on Stone (1763) ‘An account of the success of the bark of the willow in the cure of the agues’ , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.

[57]  Kirsten Bibbins-Domingo,et al.  Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. , 2016, Annals of internal medicine.

[58]  E. Hawk,et al.  Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention , 2017, Cancer and Metastasis Reviews.

[59]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[60]  P. Görög,et al.  The biologic background to some therapeutic uses of aspirin. , 1983, The American journal of medicine.

[61]  Boleslav Lichterman,et al.  Aspirin: The Story of a Wonder Drug , 2004, BMJ : British Medical Journal.

[62]  Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials , 2017, BMC Cancer.

[63]  C. Patrono,et al.  Low-dose aspirin is a selective inhibitor of platelet cyclooxygenase activity in healthy subjects. , 1983, Advances in prostaglandin, thromboxane, and leukotriene research.

[64]  J. Vane,et al.  Aspirin and Other Salicylates , 1993 .

[65]  R. Handin The History of Antithrombotic Therapy: The Discovery of Heparin, the Vitamin K Antagonists, and the Utility of Aspirin. , 2016, Hematology/oncology clinics of North America.

[66]  G. Pasero,et al.  [The Italian contributions to the history of salicylates]. , 2011, Reumatismo.

[67]  A. Algra,et al.  A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. , 1991, The New England journal of medicine.